Skyrizi Alternatives Compared
| Skyrizi (risankizumab) | Otezla (apremilast) | Taltz (ixekizumab) |
|
|---|
| Skyrizi (risankizumab) | Otezla (apremilast) | Taltz (ixekizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It may also be used to treat plaque psoriasis... View more |
Prescription only
Taltz is a monoclonal antibody that reduces inflammation and may be used to treat conditions such as psoriasis, psoriatic arthritis, or ankylosing spondylitis. It is given by injection just under the... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Skyrizi (risankizumab) | More about Otezla (apremilast) | More about Taltz (ixekizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Skyrizi has an average rating of 8.0 out of 10 from a total of 58 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 14% reported a negative effect. |
Otezla has an average rating of 5.2 out of 10 from a total of 440 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 40% reported a negative effect. |
Taltz has an average rating of 7.2 out of 10 from a total of 223 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 22% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Skyrizi side effects |
View all Otezla side effects |
View all Taltz side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Skyrizi prices |
View all Otezla prices |
View all Taltz prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
672 hours |
9 hours |
312 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 187 drugs are known to interact with Skyrizi:
|
A total of 110 drugs are known to interact with Otezla:
|
A total of 187 drugs are known to interact with Taltz:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
April 23, 2019 |
March 21, 2014 |
March 22, 2016 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Vtama
Vtama (tapinarof) is a steroid-free, once-daily cream used to treat plaque psoriasis and atopic ...
Humira
Humira is a tumor necrosis factor blocker that is used to treat many inflammatory conditions such ...
Medrol
Medrol is used for allergic rhinitis, asthma, asthma, acute, asthma, maintenance, congenital ...
Rinvoq
Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, psoriatic arthritis, atopic ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.